4.5 Review

Should epileptiform discharges be treated?

Journal

EPILEPSIA
Volume 56, Issue 10, Pages 1492-1504

Publisher

WILEY
DOI: 10.1111/epi.13108

Keywords

Antiepileptic drugs; Cognition; Epileptiform discharges; Memory; Sleep

Funding

  1. Fundacion Alfonso Martin Escudero
  2. HHV6 Foundation
  3. Patient-Centered Outcomes Research Institute
  4. Payer Provider Quality Initiative
  5. American Epilepsy Society
  6. Epilepsy Foundation of America
  7. Epilepsy Therapy Project
  8. Pediatric Epilepsy Research Foundation
  9. Citizens United for Research in Epilepsy (CURE)
  10. Danny Did Foundation
  11. Eisai Inc
  12. Lundbeck
  13. Upsher Smith
  14. U.S. Department of Defense
  15. NINDS [NS-78333]
  16. UCB
  17. Heffer Family Foundation
  18. Barry Segal Family Foundation
  19. Abbe Goldstein/Joshua Lurie family
  20. Laurie Marsh/Dan Levitz family
  21. National Institutes of Health (NIH) [NS-78333, NS43209, NS20253, NS45911]

Ask authors/readers for more resources

To evaluate the impact of epileptiform discharges (EDs) that do not occur within seizure patterns - such as spikes, sharp waves or spike waves - on cognitive function and to discuss the circumstances under which treatment of EDs might be considered. Methods used in this article is Review of the literature. EDs may disrupt short-term cognition in humans. Frequent EDs for a prolonged period can potentially impair long-term cognitive function in humans. However, there is conflicting evidence on the impact of EDs on long-term cognitive outcome because this relationship may be confounded by multiple factors such as underlying etiology, seizures, and medication effects. Limitations of existing studies include the lack of standardized ED quantification methods and of widely accepted automated spike quantification methods. Although there is no solid evidence for or against treatment of EDs, a non-evidence-based practical approach is suggested. EDs in otherwise asymptomatic individuals should not be treated because the risks of treatment probably outweigh its dubious benefits. A treatment trial for EDs may be considered when there is cognitive dysfunction or regression or neurologic symptoms that are unexplained by the underlying etiology, comorbid conditions, or seizure severity. In patients with cognitive or neurologic dysfunction with epilepsy or EDs, treatment may be warranted to control the underlying epileptic syndrome. EDs may cause cognitive or neurologic dysfunction in humans in the short term. There is conflicting evidence on the impact of EDs on long-term cognitive outcome. There is no evidence for or against treatment of asymptomatic ED.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available